Filter By Industry
Select One Biotech Business Health
Filter By Tag
Select One Biotechnology Clinical Study Results Clinical Trial Clinical Trials Drug Drug Development Drugs Hiv Aids HIV/AIDS Vaccine Immune Response Biopharma Immune Response BioPharma Inc. Inc Inc. Treatment MS MS multiple sclerosis Multiple Sclerosis NeuroVax Orphan Designation Patent Poison Pill Psoriasis Ra RA Rheumatoid Arthritis RA Rheurmatoid Arthritis RAVAX REMUNE REMUNE HIV AIDS Vaccine REMUNE vaccine Rheumatoid Arthritis Rheumatoid Arthritis RA Study TCR Peptides Therapeutic Vaccine Therapeutic Vaccines Treatment Vaccine Vaccines
Immune Response BioPharma, Inc. Press releases1 - 10 of 23 Press Releases
May 19, 2013
Immune Response BioPharma, Inc. Sets Pricing of REMUNE Vaccine in Thailand Between $75-100 Per Dose for Emergency Approval of HIV/AIDS Vaccine
Apr 21, 2013
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine
Mar 13, 2013
Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc.
Feb 05, 2013
Immune Response BioPharma, Inc. Selects the American Stock Transfer & Trust Company as Transfer Agent of Record.
Jan 07, 2013
Immune Response BioPharma, Inc. Posts 2nd Half 2012 & Full Year Results
Dec 17, 2012
Immune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS
Dec 10, 2012
Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.
Nov 21, 2012
Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision
Nov 03, 2012
Immune Response BioPharma, Inc. to Develop Zorcell Psoriasis Vaccine the First Vaccine for Psoriasis & Reviews Phase II Results
Oct 31, 2012
Immune Response BioPharma, Inc. Publishes Phase III Full 806 Study Results, REMUNE Very Effective Demonstrating 0.7% HIV Progression vs 6% Estimated Rate & Subgroup Median Virologic Failure Delayed by 20 Weeks In REMUNE Group.
RSS Feed for Immune Response BioPharma, Inc. Press Releases